Rimegepant 75 mg exposure, safety, and tolerability are similar in elderly and nonelderly adults: A phase 1, open-label, parallel-group, single-dose study

The requested reference [9954b2d66af87d1d613f77a3e4fb7b433d3a3af9] no longer exists in our database. It has been replaced by the current reference: [80e8966b59ae29e096012faf2520f210fce22764]

Authors
Category Primary study
JournalNeurology
Year 2020
This article has no abstract
Epistemonikos ID: 245bf025b4b14c52cd6574185c651e82ca94c3e7
First added on: Feb 12, 2025